Building a leading microbiome company in oncology

We are the first company developing microbiome-based drugs listed on the regulated market of Euronext Paris.

Stock information

  • IPO date: November 8, 2021
  • Denomination: MaaT Pharma
  • ISIN code/ticker: FR001263482 / MAAT
  • ICB classification: 20103010 – Biotechnology
  • Listing market: Euronext Paris regulated market
  • Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
  • Analysts covering the share:
    • KBC Securities: Thomas Vranken & Jeroen Van den Bossche
    • Kempen: Ingrid Gafanhao, Suzanne van Voorthuizen & René Wouters
    • Portzamparc Groupe BNP Paribas: Mohamed Kaabouni

Download our corporate presentation

Board of Directors

Jean-Marie Lefevre

Chairman of the Board – Non-Executive Director

Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.

Engineering degree Ecole Centrale Paris, MBA from Insead

Jean Volatier

Non-Executive Independant Director

Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l'Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.

CFO

Dr. Claude Bertrand

Non-Executive Independant Director

Claude joined MaaT Pharma as an independent board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.

PharmD, PhD

Dorothée Burkel

Non-Executive Independant Director

Dorothée Burkel holds a Master's degree from the Institut d'Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.

Chief Corporate and People Operations Officer

Isabelle de Crémoux

Non-Executive Director

Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.

Engineering degree from Ecole Centrale Paris

Muriel Prudent

Observer

Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan

Hervé Affagard

CEO, Founder

Hervé Affagard is the CEO and founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. He founded MaaT Pharma in late 2014 together with onco-hematologist Prof. Mohammad Mohty and microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Hervé is also a board member for the French biotech industry association, France Biotech and an active contributor to Allliance Promotion Microbiote, an organization recently founded to support the microbiome sector development in France.

Engineer, MBA,

Documentation

R&D Day – 06/07/2022
Replay & Presentation

H.C Wainwright Bioconnect
2022 conference
Replay

Corporate update:
Positive Results for MaaT013
From Phase 2 Clinical Trial and Early Access Program

Supplement to the Registration Document

Registration document

Corporate presentation 2022

Operation note

Webcast – 12/13/2021
Replay & Presentation

2021 Annual Financial Report
(Only in French)

Regulated information

05/31/22

Information on the compensation of corporate officers

04/04/22
Monthly information regarding the total number of
voting rights and shares comprising the share capital

02/09/22
Number of Shares and Voting Rights
Document in French

Number of voting rights as at Jan 26 2022

01/03/22
Number of Shares and Voting Rights
Document in French

Market Ethics Charter

Internal rules of the Board of Directors
Document in French

General Meetings

May, 31, 2022: Annual Combined General Meeting documents

Result of the vote on the resolutions of the annual combined
general meeting (ordinary and extraordinary)
of May 31, 2022
Document in French only

Meeting Notice
May, 31 2022

Board report EGM
May, 31 2022

AGM Convening notice 2022
May 31, 2022

Request for additional document
May 31, 2022

AGM – Special report Free shares
May 31, 2022

Special report on Stock Options
May 31, 2022

Text of resolutions AGM
May, 31 2022

List of Directors and CEO
May 31, 2022

Number of voting rights
as of April 25th, 2022

Notice of meeting BALO announcement
Only in French

AGM voting form

May 31, 2022: Statutory Auditors Reports (Documents in French only)

Rapport Audit
12/31/21

Rapport Emission BSA

Attestation Rémunération
12/31/21

Augmentation Capital Epargne Salariale

Augmentation de capital

Rapport Comptes Annuels
31/12/2021

Rapport spécial
31/12/2021

March 3, 2022: Combined General Meeting (ordinary & extraordinary)

Result of the vote on the resolutions of the combined
general meeting (ordinary and extraordinary)
of March 3rd, 2022
Document in French only

Convening notice 2022
March, 3 2022

 General Meeting voting form
March 3rd, 2022

Report of the board – combined general meeting
March 3, 2022

Auditors’ report on the share capital decrease
Document only in French

List of directors and CEO

Ordinary and Extraordinary Shareholders’ General Meeting
Press Release

Notice of meeting to the Ordinary and Extraordinary General Meeting
Document in French

Provisional financial calendar*

2022

  • July 28, 2022 – Revenues and Cash Position Quarter 2
Add to calendar
  • September 29, 2022 – Half-year results 1
Add to calendar
  • November 08, 2022 – Revenues and Cash Position Quarter 3
Add to calendar

*Indicative calendar could be subject to change.

Investor contacts

MaaT Pharma
70 avenue Tony Garnier
69007 Lyon
Email: invest@maat-pharma.com
Phone: +33 (0) 4 28 29 14 00

Hervé Affagard

CEO and co-founder

Siân Crouzet

Chief Financial and Operations Officer